European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

Alport Syndrome Clinical Trial

Official title: European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies

Status Recruiting

Clinical Trial Summary

The hereditary type IV collagen disease Alport syndrome inevitably leads to end-stage renal disease. Currently there are no therapies known to improve outcome. Our non-interventional, observational study investigates, if medications such as ACE-inhibitors can (1) delay time to dialysis and (2) improve life-expectancy within three generations of Alport-families in Europe.

Clinical Trial Description

Early diagnosis in children with Alport syndrome (AS) with isolated hematuria opens a "window of opportunity" for early intervention. Currently there are no causal therapeutic options which are proven to delay renal failure in AS. ACE-inhibition (ACEi) has been shown to reduce proteinuria in Alport patients and to delay renal failure in Alport-mice suggesting it may be of value as an effective treatment to delay renal failure in humans. To test this we established the European Alport Registry to collect data over several generations of Alport families across Europe. Small children with AS first develop microscopic hematuria, proceeding to microalbuminuria, overt proteinuria, impaired renal function and end up with end stage renal disease. These different steps of disease enabled us to assess if earlier introduction of ACE-inhibition at earlier degrees of disease is more effective than later therapy in delaying the time to dialysis and improving life-expectancy. Heterozygous COL4A3/COL4A4 mutations result in the phenotype "familial benign hematuria" or "thin basement membrane nephropathy" (TBMN). Affected subjects typically present with hematuria. Having longtime been regarded as "benign" familial hematuria, those patients might have an increased risk to develop severe renal impairment - comparable to the findings in female XLAS carriers (see above). TBMN is not a rare disease, as at least 1% of the population is affected. For the first time, the present study compares the risk of renal impairment, end stage renal disease and premature death in between heterozygous carriers of XLAS and of ARAS mutations. Additionally, the nephroprotective effect of RAAS-blockade in patients with heterozygous Alport-mutations is evaluated. ;

Related Conditions & MeSH terms

• Alport Syndrome
• Familial Benign Hematuria
• Hematuria
• Hereditary Kidney Disease
• Kidney Diseases
• Nephritis, Hereditary
• Pediatric Kidney Disease
• Renal Insufficiency
• Syndrome
• Thin Basement Membrane Disease

• NCT number: NCT02378805
• Study type: Observational [Patient Registry]
• Source: University Hospital Goettingen
• Contact: Oliver Gross, MD
• Phone: +49-551-39-
• Email: gross.oliver@med.uni-goettingen.de
• Status: Recruiting
• Start date: July 1995
• Completion date: January 2035